Fibromyalgia-Like Pain Model Development Services
At Ace Therapeutics, we specialize in the development and application of fibromyalgia-like pain models in rodents. Our services are designed to help pharmaceutical and biotech partners assess the in vivo efficacy, mechanism of action, and safety of candidate analgesics. We provide comprehensive preclinical support, from model selection to endpoint evaluation, using validated protocols and state-of-the-art assessment tools.
Fibromyalgia is a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, and heightened pain response to pressure. Despite its prevalence, the pathophysiology of fibromyalgia remains complex, involving central sensitization, altered neurotransmitter levels, and dysfunctional pain modulation pathways. Preclinical models simulate this via:
We employ established rodent models that recapitulate clinical FM features, ensuring biological relevance and reproducibility.
| Model Type | Induction Method | Key Pathological Features |
| Reserpine-Induced | Subchronic reserpine administration | Widespread hyperalgesia, monoamine depletion |
| Acid Saline-Induced | Repeated intramuscular acidic injections | Muscle hyperalgesia, central sensitization |
| Stress-Augmented | Chronic stress + minor insult | Anxiety-like behavior, glial activation |
Model Validation
We offer integrated services that align with the pain drug development pipeline. Rather than offering static animal models, we deliver a full suite of downstream in vivo measurement and endpoint evaluation services tailored to each client's investigational compound.
Model Selection and Feasibility Studies
Pain Model Induction and Validation
Analgesic Efficacy Assessment
Behavioral endpoints:
Biological markers:
Mechanism of Action and Molecular Studies
Gene expression analysis (qPCR, RNA-seq) in brain and spinal cord
Protein-level validation via western blotting and immunohistochemistry
Electrophysiological measurements of spinal cord hyperexcitability (where applicable)
Safety and Pharmacokinetics
Toxicity observation during treatment window
Blood collection for PK analysis (LC-MS/MS quantification)
Organ tissue distribution studies (optional)
Our migraine model services are suitable for evaluating a wide range of therapeutic modalities, including:
Target validation and lead compound screening in early-stage discovery
Let Ace Therapeutics help you accelerate the development of your next-generation analgesic candidates with rigorously validated fibromyalgia-like pain models and integrated preclinical services.
Which fibromyalgia-like model is most suitable for CNS-targeting drugs?
The reserpine-induced model is particularly suitable for evaluating CNS-active drugs due to its neurochemical alterations and depression-like phenotypes.
Can you evaluate chronic dosing effects?
Yes. We support subchronic drug administration protocols and monitor both efficacy and tolerability across the dosing period.
What behavioral endpoints are available?
We offer mechanical and thermal sensitivity testing, locomotor activity, depressive-like behavior evaluation, and fatigue assessment through voluntary movement metrics.
Can the model be used to study sex differences?
Yes. Both male and female rodents can be included in the study to assess sex-specific drug responses.
Do you provide tissue samples or only raw data?
We can provide both, depending on the client's request. Tissue harvesting for downstream analysis is part of our standard service options.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics comprises a team of highly committed and skilled researchers focused exclusively on providing innovative preclinical contract research solutions for novel analgesic development. We deliver rigorous models and data essential for advancing targeted, non-addictive pain therapies toward clinical evaluation.